Literature DB >> 9565811

Continuous venovenous hemodiafiltration (CVVHDF) with citrate anticoagulation in the treatment of a patient with acute renal failure, hypercalcemia, and thrombocytopenia.

V Srámek1, I Novák, M Matĕjovic, R Rokyta, M Nalos, P Hora, H Pittrová.   

Abstract

A 72-year-old patient with multiple myeloma was admitted to the intensive care unit because of hypercalcemic crisis and acute renal failure. After 7 days of comprehensive therapy including diuretics steroids, calcitonin, and intermittent hemodialysis (IHD) with low-calcium dialysate, calcium still reached high levels between IHD treatments and thrombocytopenia developed after chemotherapy. CVVHDF with calcium-free bicarbonate dialysate was started. Anticoagulation with 2.2% citrate was performed in order to chelate calcium, and thus treat the hypercalcemia, and to provide regional anticoagulation, and thus reduce the risk of bleeding due to thrombocytopenia. CVVHDF with citrate anticoagulation was continued for 6 days, and standard heparin anticoagulation was started when the hypercalcemia and thrombocytopenia abated.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9565811     DOI: 10.1007/s001340050562

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN: 0342-4642            Impact factor:   17.440


  6 in total

1.  Regional citrate anticoagulation for continuous arteriovenous hemodialysis. An update after 12 months.

Authors:  R L Mehta; B R McDonald; D M Ward
Journal:  Contrib Nephrol       Date:  1991       Impact factor: 1.580

Review 2.  Biology and therapy of multiple myeloma in 1996.

Authors:  B Barlogie; S Jagannath; J Epstein; N Munshi; D Siegel; K R Desikan; R Feinman; P L Hsu; K von Bremen; G Tricot
Journal:  Semin Hematol       Date:  1997-01       Impact factor: 3.851

Review 3.  Continuous hemofiltration in the treatment of acute renal failure.

Authors:  L G Forni; P J Hilton
Journal:  N Engl J Med       Date:  1997-05-01       Impact factor: 91.245

Review 4.  The management of malignant hypercalcaemia.

Authors:  J Watters; G Gerrand; D Dodwell
Journal:  Drugs       Date:  1996-12       Impact factor: 9.546

5.  Renal dysfunction in multiple myeloma.

Authors:  M Uchida; K Kamata; M Okubo
Journal:  Intern Med       Date:  1995-05       Impact factor: 1.271

6.  Calcium free hemodialysis: experience in the treatment of 33 patients with severe hypercalcemia.

Authors:  C Camus; C Charasse; I Jouannic-Montier; P Seguin; Y L Tulzo; J Bouget; R Thomas
Journal:  Intensive Care Med       Date:  1996-02       Impact factor: 17.440

  6 in total
  6 in total

1.  Metastatic calcifications and severe hypercalcemia in a patient with parathyroid carcinoma.

Authors:  P Valdivielso; J López-Sánchez; A Garrido; J J Sánchez-Carrillo
Journal:  J Endocrinol Invest       Date:  2006 Jul-Aug       Impact factor: 4.256

2.  Vanishing polyuria and respiratory failure.

Authors:  Fabio Ruggieri; Alessandro Chiesa; Kathleen Schorn; Klaus Strobel; Marco Maggiorini; Christoph Schmid
Journal:  BMJ Case Rep       Date:  2010-10-21

3.  Regional citrate anticoagulation versus low molecular weight heparin anticoagulation for continuous venovenous hemofiltration in patients with severe hypercalcemia: a retrospective cohort study.

Authors:  Yan Yu; Ming Bai; Zhang Wei; Lijuan Zhao; Yangping Li; Feng Ma; Shiren Sun
Journal:  Ren Fail       Date:  2020-11       Impact factor: 2.606

4.  Treatment of extreme hypercalcaemia: the role of haemodialysis.

Authors:  Anna B Basok; Boris Rogachev; Yosef Shmuel Haviv; Marina Vorobiov
Journal:  BMJ Case Rep       Date:  2018-06-04

5.  A life-threatening duodenal ulcer hemorrhage due to previously unknown primary hyperparathyroidism.

Authors:  Dan Xie; Kunpeng Hu; Ying Xian; Ying Wang; Xiaofeng Yuan; Mingliang Li; Xiaogang Bi; Kouxing Zhang
Journal:  Gastroenterol Rep (Oxf)       Date:  2016-09-10

6.  Rapid calcium loss may cause arrhythmia in hemofiltration with regional citrate anticoagulation: a case report.

Authors:  Buyun Wu; Jing Wang; Guang Yang; Changying Xing; Huijuan Mao
Journal:  BMC Nephrol       Date:  2018-06-14       Impact factor: 2.388

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.